NBF produces the full spectrum of biologic modalities, from monoclonal antibodies and antibody-drug conjugates through to radioligand therapeutics, recombinant vaccines, Fc-fusions, nanobodies and therapeutic enzymes. Gene to clinical-grade drug substance, all under one roof.
Whichever modality your programme requires, NBF can take it from gene to clinical drug substance. The same multi-host expression, bioconjugation, downstream and analytical platforms support all modality classes, only the construct design and the chemistry of the payload differ.
Full-length IgG monoclonal antibodies are NBF's most-produced modality. Antibody discovery via phage display, humanisation and affinity maturation feed directly into CHO or HEK293 transient and stable expression, downstream Protein A capture, and Phase I clinical-grade antibody manufacture at 50 L bioreactor scale.
Engineered bispecific formats: knob-into-hole, CrossMab, common light chain, DVD-Ig and tandem scFv designs, are routinely supported. The mammalian expression platform handles the typically lower titres and quality challenges of bispecifics, with bioanalytics tuned to detect mispairing.
Smaller antibody formats: Fab, scFv, single-domain antibodies (VHH / nanobodies), are produced in E. coli, yeast, or mammalian systems depending on the application. Camelid VHH library construction and nanobody panning are run by NBF's molecular discovery group.
NBF produces the recombinant antibody backbone for ADC manufacture and operates a bioconjugation suite for site-specific and stochastic payload attachment. Cysteine-engineered antibodies (THIOMAB-style), engineered glycan handles, and sortase / transglutaminase enzymatic conjugation are all supported.
For radioligand therapy and theranostic applications, NBF supplies the recombinant targeting vector: antibody, antibody fragment, peptide or affibody: pre-conjugated with chelators (DOTA, DTPA, NOTA, deferoxamine) ready for downstream radiolabelling with 177Lu, 225Ac, 89Zr or 68Ga at a licensed radiopharmacy. We do not handle radioisotopes in-house but our bioconjugation chemistry and analytical package are designed for radiopharmaceutical-precursor specification.
Subunit vaccine antigens, stabilised viral glycoproteins (including molecular-clamp formats), virus-like particles (VLPs) and self-assembling protein nanoparticles are all within scope. NBF has supported COVID-19, Chapare, antiviral and pandemic-preparedness vaccine manufacture programmes through to Phase I clinical material.
Recombinant Fc-fusion biotherapeutics: soluble receptor traps, cytokine-Fc fusions, decoy receptors, are produced in mammalian hosts and purified via Protein A. Effector function tuning (LALA, DLE) and half-life extension via Fc engineering are routinely supported at the molecular design stage.
Recombinant therapeutic enzymes, including glycosylated and PEGylated forms, are produced across E. coli, yeast and mammalian hosts. Enzyme activity assays, structural integrity confirmation and post-translational modification analysis are baked into the standard release package.
Beyond therapeutic biologics, NBF supplies research- and diagnostic-grade recombinant proteins: assay calibrators, reference antigens, surrogate biomarkers, for academic and industry sponsors. Smaller research-scale batches feed directly into the same quality pipeline as the GMP workflows.
The same five-host expression platform, discovery group, downstream and process development capability, bioanalytical package and Phase I clinical manufacturing suite underpin every modality on this page. That means one quality system, one project team, one tech-transfer pathway, from gene through to clinical drug substance.
Australian researchers, biotech companies and global sponsors use NBF as a single-source provider for the modality classes that matter most to modern biotherapeutic development.
Whether you have a fully-characterised antibody candidate ready for tech transfer, a peptide scaffold for radioligand conjugation, a vaccine antigen needing stabilisation, or an early-stage discovery target, NBF can scope a tailored manufacturing programme for your modality.
Contact NBFNBF is proudly supported by
